Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial.
Authors
Russell, NHills, R
Kell, J
Cavanagh, J
Kjeldsen, L
McMullin, M
Cahalin, P
Dennis, Michael
Friis, L
Grech, A
Milligan, D
Clark, R
Burnett, A
Affiliation
Department of Haematology, Nottingham University Hospitals, UKIssue Date
2016